Studies related to Migraine and Feverfew

Efficacy And Safety Of 6.25 Mg T.i.d. Feverfew CO2-extract (MIG-99) In Migraine Prevention--a Randomized, Double-blind, Multicentre, Placebo-controlled Study

Effect Decrease
Trial Design Double blind
Trial Length n/a
Number of Subjects 170
Gender n/a
Notes for this study:
6.25mg of feverfew thrice a day was significantly better than placebo in reducing the occurrence of migraines, reducing an average of 4.76 attacks per month by 1.9 in feverfew and 1.3 in placebo; no significant side effects recorded

Efficacy Of Feverfew As Prophylactic Treatment Of Migraine

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 17
Gender Both Genders
Age Range 30-44, 45-64
Notes for this study:
In a sample of persons who suffer from migraines and treated with fresh feverfew leaves prior to the study, when they were given either placebo or encapsulated feverfew the placebo group had an increased rate of migraine occurrence than did the feverfew group.

The Efficacy And Safety Of Tanacetum Parthenium (feverfew) In Migraine Prophylaxis--a Double-blind, Multicentre, Randomized Placebo-controlled Dose-response Study

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 147
Gender Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Body Types Average
Notes for this study:
In a larger sample of persons suffering from migraines with or without auras, feverfew failed to be significantly different than placebo in reducing the occurrence and severity of migraines. However, it reached statistical significance in a subgroup of persons with higher rates of migraine attacks (1 per 7 days)

The Efficacy And Safety Of Tanacetum Parthenium (feverfew) In Migraine Prophylaxis--a Double-blind, Multicentre, Randomized Placebo-controlled Dose-response Study

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 147
Gender Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Body Types Average
Notes for this study:
In a larger sample of persons suffering from migraines with or without auras, feverfew failed to be significantly different than placebo in reducing the occurrence and severity of migraines. However, it reached statistical significance in a subgroup of persons with higher rates of migraine attacks (1 per 7 days)

Randomised Double-blind Placebo-controlled Trial Of Feverfew In Migraine Prevention

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 72
Gender Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Notes for this study:
Feverfew was associated with less migraine occurrence, but the duration of migraine attacks failed to be significantly different than placebo.